We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Aspacytarabine Safe and Effective in Patients with AML Unfit for Intensive Chemotherapy.
- Authors
Dawson, Charlie
- Abstract
The article presents results from a clinical trial presented during the American Society of Clinical Oncology 2021 virtual annual meeting, aspacytarabine, a prodrug of cytarabine, appears safe and effective as first-line therapy for patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Topics include how AML chemotherapy backbone for challenging patient population; and patients who achieved omplete response (CR) were minimal residual disease (MRD)-negative.
- Subjects
PATIENT safety; ACUTE myeloid leukemia; CANCER chemotherapy; OLDER people; ADVERSE health care events
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 10, p1
- ISSN
2164-4403
- Publication type
Article